Take­da bless­es a lit­tle biotech's en­gi­neered tox­in tech for mul­ti­ple myelo­ma, trig­ger­ing a bases loaded home run

Austin-based Mol­e­c­u­lar Tem­plates scored three times on Wednes­day. 

Ear­ly in the day the biotech an­nounced a deal with Take­da to take their 2-year pre­clin­i­cal odyssey up to the prover­bial next lev­el, an­gling to take an en­gi­neered tox­in tech in­to the clin­ic. Take­da’s Boston R&D group — about to un­der­go a mon­u­men­tal trans­for­ma­tion with the Shire takeover — inked the pact, hand­ing over $30 mil­lion in cash and promis­ing a rich ta­pes­try of mile­stones that to­taled in the hun­dreds of mil­lions of dol­lars.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER